InVivo Therapeutics announced that James Cook University Hospital in Middlesbrough, United Kingdom, has been added as the U.K.’s first clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The Golden Jubilee Regional Spinal Cord Injuries Centre located at the James Cook University Hospital, a major trauma center, focuses exclusively on patients with spinal cord injuries and is one of eight specialist centers within England.
“I am enthusiastic about the opportunity to be joining the INSPIRE study and I look forward to helping InVivo evaluate this exciting experimental technology while bringing awareness of the study to the United Kingdom,” Dr. Prasad said.
Mark Perrin, InVivo’s CEO and chairman, said, “We are thrilled to open our first INSPIRE site in the United Kingdom and are looking forward to working with Dr. Prasad and the staff at James Cook University Hospital. The INSPIRE Study is now open for enrollment across three countries: the United States, Canada and the United Kingdom.”
There are now 33 clinical sites participating in the clinical study:
The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate the safety and probable benefit of the Neuro-Spinal Scaffold for the treatment of complete T2-T12/L1 spinal cord injury in support of a Humanitarian Device Exemption (HDE) application for approval.